为您找到相关结果约121个

你是不是要搜索 期刊Savolitinib结合模式共晶 点击跳转

Savolitinib: A Promising Targeting Agent for Cancer

Savolitinib for non-small cell lung cancer

SAVOLITINIB - A SAVIOUR FOR PAPILLARY RCC?

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer

Savolitinib for MET-driven papillary renal cell carcinoma

Savolitinib Hepatocyte growth factor receptor (HGFR, MET, c-Met) inhibitor Cancer therapy

Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib

NON-SMALL CELL LUNG CANCER RESPONDS TO OSIMERTINIB PLUS SAVOLITINIB

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer

Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric

Savolitinib +/- Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b

Effect of food on the single-dose pharmacokinetics and tolerability of savolitinib in Chinese healthy

为您找到相关结果约121个

共121条页码: 1/9页15条/页